Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Sep 17, 2024 5:03pm
61 Views
Post# 36227894

RE:RE:RE:RE:How does Accelerated Approval work

RE:RE:RE:RE:How does Accelerated Approval work
The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint. 

And the FDA's Accelerated Approval is based on the above, and further objective criteria of therapeutic durability/clinical benefit, evidence of sufficient patient enrollment into an FDA approved late-stage/confirmatory clinical trial, and proof of GMP manufacturing capability - which is criteria that ONCY has met or will meet with its PR that their extended Phase2b->Phase3->Confirmatory trial has started - which is expected later this year or early next.  


By this time ONCY will have either announced a partner and/or a Big Pharma acquirer, who will then register for an Accelerated Approval and run the confirmatory trial on their own time-line.

A confirmatory trial could simply be following the cohort you have enrolled in your registration trial, Peter Marks, MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at the FDA, such that a company's Phase 1/2 cohort is simply reconsidered as the Phase 3/ Confirmatory trial to the Accelerated Approval product. 
 
<< Previous
Bullboard Posts
Next >>